Invetso Quality Score — CCEL

Cryo-Cell International, Inc. · 3.6/10 — Weak · Updated September 2026

3.6Weak

Last updated: September 2026

Factor Snapshot

Durability🔴 Weak
Capital Efficiency🔴 Weak
Growth Quality🟡 Moderate
Risk Profile🔴 Weak
Capital Allocation🟡 Moderate
Scalability🟡 Moderate

Invetso Quality Score

🔴 3.6 (Weak)

Core Drivers

No durable moat to protect returns: The business shows little evidence of pricing power, switching costs, network effects, or efficient-scale protection, so its competitive position is not strong enough to defend returns against peers over time.

Capital is not compounding effectively: Negative ROIC and weak cash conversion indicate that current capital deployment is not translating into durable value creation, which is a major drag on long-term investment quality.

Defensive demand helps, but not enough: The underlying service demand is relatively stable and low capex supports resilience, but that stability has not converted into strong growth quality or superior operating leverage.

Peer-relative profile is clearly weaker: Against global peers, the company looks lagging rather than leading because leverage, liquidity, and capital efficiency are materially less favorable than stronger operators in the same broad space.

Key Constraints

Balance-sheet strain limits flexibility: Very high leverage and negative interest coverage materially reduce strategic freedom, making the company more vulnerable to financing pressure and less able to fund growth or absorb shocks.

Growth upside is not well evidenced: The provided data do not show convincing multi-year compounding, and the current operating profile does not yet demonstrate scalable expansion that would justify a stronger quality assessment.

Downside asymmetry remains unfavorable: Because the business lacks a strong moat and has limited liquidity cushion, any operational softness can flow quickly into weaker returns and tighter financial conditions.

Synthesis

CCEL’s investment profile is defined more by resilience than by strength, but resilience alone is not enough to offset the absence of a durable competitive edge. The business benefits from relatively defensive demand and low capital intensity, yet those positives are outweighed by weak capital efficiency, limited evidence of scalable compounding, and a balance sheet that materially constrains flexibility. The most important issue is that capital is not currently earning attractive returns, so even stable operations do not translate into strong long-term quality. Relative to global peers, the company sits below average because it lacks the structural advantages and financial strength that typically support durable outperformance. The result is a profile with limited upside asymmetry and meaningful downside sensitivity if operating conditions soften. Overall, the company reads as a lower-quality franchise within its peer set rather than a leading one.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Cryo-Cell International, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →